John Wiley & Sons Inc. Common Stock (NYSE:WLYB)

Real-time price: | Most recent change:0.00%

JOHN WILEY & SONS, INC. is a global publisher of print and electronic products, providing content and solutions to customers worldwide. The Company's core businesses produce professional and consumer books and subscription products; scientific, technical, medical and scholarly journals, encyclopedias, books, and online products; and textbooks and educational materials, including integrated online teaching and learning resources, for undergraduate and graduate students, teachers and lifelong learners. The Company's three core businesses develop and cross-market products to its diverse customer base of professionals, consumers, researchers, students, and educators....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 28 February 2026

Blog+More

Facebook, Google, and Twitter attend a U.S. House testimony on whether these tech titans filter web content for political reasons.

Amy Hamilton

2018-07-15 11:35:00 Sunday ET

Facebook, Google, and Twitter attend a U.S. House testimony on whether these tech titans filter web content for political reasons.

Facebook, Google, and Twitter attend a U.S. House testimony on whether these social media titans filter web content for political reasons. These network pla

+See More

President Trump praises great unity and progress at the G7 summit.

Rose Prince

2019-09-21 09:25:00 Saturday ET

President Trump praises great unity and progress at the G7 summit.

President Trump praises great unity and progress at the G7 summit with respect to Sino-U.S. trade conflict resolution, global climate change, containment fo

+See More

A small fraction of the population enjoys most capital and wealth creation.

Jacob Miramar

2017-03-15 08:46:00 Wednesday ET

A small fraction of the population enjoys most capital and wealth creation.

The heuristic rule of *accumulative advantage* suggests that a small fraction of the population enjoys a large proportion of both capital and wealth creatio

+See More

The Economist interviews President Trump and spots the keyword *reciprocity* from trade to taxation.

Amy Hamilton

2017-07-01 08:40:00 Saturday ET

The Economist interviews President Trump and spots the keyword *reciprocity* from trade to taxation.

The Economist interviews President Donald Trump and spots the keyword *reciprocity* in many aspects of Trumponomics from trade and taxation to infrastructur

+See More

Generative artificial intelligence (Gen AI) uses large language models (LLM) to create online contents with better human productivity.

Monica McNeil

2024-10-31 09:26:00 Thursday ET

Generative artificial intelligence (Gen AI) uses large language models (LLM) to create online contents with better human productivity.

Generative artificial intelligence (Gen AI) uses large language models (LLM) and content generation tools to enhance human lives with better productivity.

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More